(Q38152942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Appraising iniparib, the PARP inhibitor that never was--what must we learn? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Michael Ong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

David Tan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Joaquin Mateo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Michael A Gonzalez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Johann S de Bono

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

15 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

688-696

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

Phase III and submission failures: 2007–2010

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Rapidly rising clinical trial costs worry researchers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Delivering affordable cancer care in high-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

High drug attrition rates--where are we going wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Preclinical development of molecular-targeted agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Translating clinical trials into meaningful outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Drug development: Raise standards for preclinical cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Believe it or not: how much can we rely on published data on potential drug targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Challenges of PK/PD measurements in modern drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Drug penetration in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Telomerase as a Target for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Translating cancer research into targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Limits on Medicare's ability to control rising spending on cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Why do phase III clinical trials in oncology fail so often?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

How valid are claims for synergy in published clinical studies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.177

Comparison of the cytotoxic and antiretroviral effects of 3-nitrosobenzamide and 4-iodo-3-nitrobenzamide

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24129347

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24129347

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cancer cell selectivity of 5-iodo-6-aminobenzopyrone (INH2BP) and methyl-3,5-diiodo-4(4'-methoxyphenoxy) benzoate (DIME)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24129347

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.177

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24129347%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference